Claimed first and only generic competitor to Advair launched in USA

21 April 2017

Israeli generics giant Teva Pharmaceutical Industries (NYSE: TEVA) today announced the simultaneous US launch of AirDuo RespiClick (fluticasone propionate and salmeterol) inhalation powder and its authorized generic for the treatment of asthma in patients aged 12 years and older who are uncontrolled on an inhaled corticosteroid (ICS) or whose disease severity clearly warrants the use of an ICS/long-acting beta2-adrenergic agonist (LABA) combination.

These will be the first direct competition to UK pharma major GlaxoSmithKline's (LSE: GSK) best-selling Advair, which generated sales of £1.83 billion ($2.35 billion) in 2016. "Neither branded AirDuo, nor its authorized generic are therapeutically equivalent or substitutable for Advair," according to a GSK spokesperson.

Teva is launching both products at the same time in an effort to address the need for more affordable asthma treatment options in the USA. Teva expects that sales of the authorized generic will represent most of the sales of the two products.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK